Global Collaboration Surge Drives AI Pharma into a New Era of Deep Integration

　　【Pharmaceutical Network - Industry Dynamics] With the continuous advancement of artificial intelligence (AI) technologies, pharmaceutical companies are heavily investing in AI-driven drug discovery. The pharmaceutical industry aims to leverage AI to make the entire research and development process faster and more predictable. Since 2026, a large number of leading enterprises, including Eli Lilly, Sanofi, and Novo Nordisk, have entered into licensing agreements with AI companies. Statistical data shows that over 50 licensing agreements were concluded in the first four months of 2026 alone, a figure nearly equivalent to the total for the entire year of 2025. Nevertheless, the trend of collaborations in AI-driven drug discovery continues.
 

Recently, AI-driven drug design company Protillion Biosciences entered into a collaboration and licensing agreement with Merck & Co., Inc. (MSD), with a total potential value of $510 million. The core of this partnership relies on Protillion’s proprietary Prot-MaP technology. The Prot-MaP platform can autonomously generate large volumes of standardized training data and is equipped with quantitative analysis capabilities for protein libraries, directly addressing the common issue of overfitting in AI models. Traditional AI approaches, which rely solely on public databases, often yield protein molecules that demonstrate strong in vitro efficacy but poor in vivo druggability. According to the announcement, this platform effectively mitigates the problem of AI model overfitting and enables the identification of optimized biologic drug candidates with complex therapeutic properties.
 

In the domestic market, Harbour BioMed and BioMap recently announced the establishment of a comprehensive strategic partnership characterized by multi-layered collaboration and long-term commitment. The partnership focuses on AI-driven research and development of complex macromolecular drugs, aiming to systematically address bottlenecks and challenges in the development of next-generation innovative therapies and jointly build a competitive R&D ecosystem.
 

It is reported that this collaboration focuses on therapeutic areas for chronic diseases. Cardiovascular, Renal, and Metabolic (CVRM) disorders, Central Nervous System (CNS) conditions, and anti-aging are health issues that broadly impact human well-being, representing significant unmet clinical needs and key areas of strategic investment for many multinational corporations (MNCs) and biotechnology companies. Under the strategic cooperation framework, the two parties will jointly establish a novel AI-driven pipeline development company targeting the global market—MegaStream TechBio. As a co-founder, BioMap will provide foundational AI technology empowerment, model engineering support, and intelligent R&D capabilities. The initial pipeline will comprise both AI-enabled drug discovery projects from prior collaborations and newly initiated AI-native pipeline development projects.
 

XtalPi recently announced that it has entered into a strategic AI drug discovery collaboration with an international biopharmaceutical company, with a total value exceeding $400 million. The two parties will jointly develop innovative oral small-molecule drugs with “Best-in-Class” potential, focusing on a GPCR (G protein-coupled receptor) target.
 

Judging from the collaborative strategies of major pharmaceutical companies, the AI-driven drug discovery industry has moved beyond the early stage of simple tool-based enablement. Whereas AI was previously limited to isolated tasks such as drug molecule screening and compound design, it is now permeating the entire R&D process, achieving intelligent upgrades across the full chain—from target discovery and molecular optimization to preclinical validation. Meanwhile, industry collaborations are shifting from short-term project licensing to deeply integrated models characterized by long-term joint ventures for platform co-construction and collaborative pipeline development.
 

Nevertheless, amid the industry’s rapid development, challenges persist. One institution noted that a 2024 study of more than 100 AI-focused biotechnology companies found that the success rate of AI-designed drugs in Phase I clinical trials—where the primary focus is on assessing drug safety—exceeded 80%, far higher than the historical average of approximately 40% to 60%. However, researchers found that AI appeared to lose its advantage thereafter. In Phase II clinical trials—where the efficacy of therapies is validated—the success rate for AI-developed drugs was only about 40%, roughly on par with the industry average.
 

Overall, AI is set to rewrite the underlying logic of pharmaceutical R&D, with end-to-end intelligence and deeply integrated collaborations becoming an irreversible trend in the industry. To truly unlock the full value of AI-driven drug discovery in the future, the industry must not only focus on early-stage algorithm optimization and data iteration but also break down the barriers between AI models and real-world clinical scenarios, optimizing algorithmic logic to align with the needs of clinical trials.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice for any person.